Related Experiment Video
Updated: Dec 15, 2025
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Chimeric antigen receptor signaling: Functional consequences and design implications
S E Lindner1, S M Johnson1, C E Brown2
1Department of Immuno-Oncology, Beckham Research Institute, City of Hope National Medical Center, Duarte, CA, USA.
Abstract:
Chimeric antigen receptor (CAR) T cell therapy has transformed the care of refractory B cell malignancies and holds tremendous promise for many aggressive tumors. Despite overwhelming scientific, clinical, and public interest in this rapidly expanding field, fundamental inquiries into CAR T cell mechanistic functioning are still in their infancy. Because CAR T cells are manufactured from donor T lymphocytes, and because CARs incorporate well-characterized T cell signaling components, it has largely been assumed that CARs signal analogously to canonical T cell receptors (TCRs). However, recent studies demonstrate that many aspects of CAR signaling are unique, distinct from endogenous TCR signaling, and potentially even distinct among various CAR constructs. Thus, rigorous and comprehensive proteomic investigations are required for rational engineering of improved CARs. Here, we review what is known about proximal CAR signaling in T cells, compare it to conventional TCR signaling, and outline unmet challenges to improving CAR T cell therapy.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for aggressive tumors. New research reveals CAR T cell signaling is unique, not like T cell receptors (TCRs), requiring further study for improved therapies.
Area of Science:
- Immunology and Cancer Therapy
- Cellular Signaling Mechanisms
Background:
- Chimeric antigen receptor (CAR) T cell therapy has revolutionized B cell malignancy treatment.
- CAR T cell therapy holds significant promise for various aggressive cancers.
- Fundamental understanding of CAR T cell mechanistic functioning remains limited.
Purpose of the Study:
- To review current knowledge of proximal CAR T cell signaling.
- To compare CAR T cell signaling with conventional T cell receptor (TCR) signaling.
- To identify challenges and unmet needs in improving CAR T cell therapy.
Main Methods:
- Review of existing scientific literature on CAR T cell signaling.
- Comparative analysis of CAR signaling pathways versus endogenous TCR signaling.
- Identification of knowledge gaps through critical assessment of current research.
Main Results:
- CAR T cell signaling is not analogous to canonical TCR signaling.
- Significant differences exist between CAR signaling and endogenous TCR signaling.
- CAR signaling may vary considerably among different CAR constructs.
Conclusions:
- Rigorous proteomic investigations are essential for advancing CAR T cell therapy.
- Understanding unique CAR signaling is crucial for rational engineering of improved CARs.
- Addressing current challenges will enhance the efficacy and application of CAR T cell treatments.
